IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway


Although the Th17 subset and its signature cytokine, interleukin (IL)-17A (IL-17), are implicated in certain autoimmune diseases, their role in cancer remains to be further explored. IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear. We show that growth of B16 melanoma and MB49 bladder carcinoma is reduced in IL-17(-/-) mice but drastically accelerated in IFN-gamma(-/-) mice, contributed to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor growth. Adoptive transfer studies and analysis of the tumor microenvironment suggest that CD4(+) T cells are the predominant source of IL-17. Enhancement of tumor growth by IL-17 involves direct effects on tumor cells and tumor-associated stromal cells, which bear IL-17 receptors. IL-17 induces IL-6 production, which in turn activates oncogenic signal transducer and activator of transcription (Stat) 3, up-regulating prosurvival and proangiogenic genes. The Th17 response can thus promote tumor growth, in part via an IL-6-Stat3 pathway.

DOI: 10.1084/jem.20090207

Extracted Key Phrases

4 Figures and Tables

Citations per Year

2,248 Citations

Semantic Scholar estimates that this publication has 2,248 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Wang2009IL17CP, title={IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway}, author={Lin Wang and Tangsheng Yi and Marcin Kortylewski and Drew M. Pardoll and Defu Zeng and Hua Yu}, booktitle={The Journal of experimental medicine}, year={2009} }